Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: a retrospective analysis

Aim. The aim of this study was to compare the efficacy and tolerability of solifenacin and mirabegron in patients with overactive bladder (OAB) syndrome. Methods. We carried out a retrospective analysis in 342 women affected by OAB syndrome; 168 were treated with solifenacin 5mg/daily and 174 with mirabegron 50mg/daily. A clinical evaluation, 3-day voiding diary, and urodynamic testing was performed. Patients completed the Overactive Bladder Questionnaire - Short Form, the King's Health Questionnaire, and the Patient Global Impression of Improvement questionnaire. The adverse effects were evaluated. The two groups were compared at baseline and at 12weeks. Results. After 12weeks, a significant reduction in the mean number/24h of voids and urgent micturition episodes/24h was observed in both groups. Detrusor overactivity decreased from 58.3% to 13.1% in the solifenacin group and from 58% to 11% in the mirabegron group. Twenty (12%) and 18 (10.7%) patients taking solifenacin reported constipation and dry mouth, respectively, versus four (2.3%) and five (2.9%) patients taking mirabegron, respectively, but there was no difference between the groups in the change in vital signs. The Overactive Bladder Questionnaire - Short Form and King's Health Questionnaire scores did not demonstrate significant differences and the abandonment rates in the solifenacin and mirabegron groups were 25.5% and 20%, respectively. Conclusion. Solifenacin and mirabegron showed the same efficacy in the treatment of OAB but solifenacin had more adverse effects.